Citation

Mead A. Epilepsy Behav. 2017; 70(Pt B): 288-291.

Affiliation

GW Pharmaceuticals, Inc., 5800 Armada Dr., Suite 210, Carlsbad, CA 92008, United States. Electronic address: apm@gwpharm.com.

Copyright

(Copyright © 2017, Elsevier Publishing)

DOI

10.1016/j.yebeh.2016.11.021

PMID

28169144

Abstract

In the United States, federal and state laws regarding the medical use of cannabis and cannabinoids are in conflict and have led to confusion among patients, caregivers, and healthcare providers. Currently, cannabis is legal for medical purposes in 50% of the states, and another seventeen states allow products that are high in cannabidiol (CBD) and low in THC (tetrahydrocannabinol) for medical use. Many of these artisanal products are sold in dispensaries or over the internet. However, none of these products has been approved by the Food and Drug Administration (FDA). Understanding how federal laws apply to clinical research and practice can be challenging, and the complexity of these laws has resulted in particular confusion regarding the legal status of CBD. This paper provides an up-to-date overview (as of August 2016) of the legal aspects of cannabis and cannabidiol, including cultivation, manufacture, distribution, and use for medical purposes. This article is part of a Special Issue title, Cannabinoids and Epilepsy.

Copyright © 2017 The Author. Published by Elsevier Inc. All rights reserved.

Language: en

Keywords

Cannabidiol; Cannabinoids; Cultivation; Hemp; Medical use; Transportation